8.04
2.55%
-0.21
After Hours:
8.05
0.01
+0.12%
Adverum Biotechnologies Inc stock is currently priced at $8.04, with a 24-hour trading volume of 1.79M.
It has seen a -2.55% decreased in the last 24 hours and a -29.16% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $8.39 pivot point. If it approaches the $8.01 support level, significant changes may occur.
Previous Close:
$8.25
Open:
$8.17
24h Volume:
1.79M
Market Cap:
$166.89M
Revenue:
-
Net Income/Loss:
$-117.17M
P/E Ratio:
-6.0451
EPS:
-1.33
Net Cash Flow:
$-91.71M
1W Performance:
-13.55%
1M Performance:
-29.16%
6M Performance:
+793.33%
1Y Performance:
+917.08%
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
650-272-6269
Address
1035 O'Brien Drive, Suite A, Menlo Park, CA
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-07-22 | Upgrade | Truist | Hold → Buy |
Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Apr-29-21 | Downgrade | Truist | Buy → Hold |
Dec-16-20 | Initiated | UBS | Neutral |
Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
May-13-20 | Initiated | RBC Capital Mkts | Outperform |
May-05-20 | Upgrade | SunTrust | Hold → Buy |
Apr-28-20 | Initiated | Goldman | Buy |
Mar-16-20 | Initiated | SVB Leerink | Outperform |
Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
Jun-14-19 | Resumed | Raymond James | Mkt Perform |
Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
Aug-30-18 | Initiated | SunTrust | Buy |
Feb-15-18 | Resumed | Piper Jaffray | Overweight |
Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? - MSN
MSN
Adverum Biotechnologies' (ADVM) “Buy” Rating Reaffirmed at Truist Financial - Defense World
Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Up 6.2% in April - MarketBeat
MarketBeat
Long Term Trading Analysis for (ADVM) - Stock Traders Daily
Stock Traders Daily
Truist Financial Reiterates Buy Rating for Adverum Biotechnologies (NASDAQ:ADVM) - MarketBeat
MarketBeat
Monitoring Adverum Biotechnologies Inc (ADVM) after recent insider movements – Knox Daily - Knox Daily
Knox Daily
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Adverum Biotechnologies Inc (ADVM) Net Income 2024
ADVM net income (TTM) was -$117.17 million for the quarter ending December 31, 2023, a +24.18% increase year-over-year.
Adverum Biotechnologies Inc (ADVM) Cash Flow 2024
ADVM recorded a free cash flow (TTM) of -$91.71 million for the quarter ending December 31, 2023, a +23.52% increase year-over-year.
Adverum Biotechnologies Inc (ADVM) Earnings per Share 2024
ADVM earnings per share (TTM) was -$11.60 for the quarter ending December 31, 2023, a +25.16% growth year-over-year.
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Cap:
|
Volume (24h):